Diabetes and COVID-19: Role of insulin resistance as a risk factor for COVID-19 severity

doi:10.4239/wjd.v12.i9.1550

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6997)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

526

WORD

222

HTML

4658

Figures (1-2)

167

Tables (1-1)

163

Sum=5736

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

456

Download

805

Sum=1261

Sep 15, 2021 (publication date) through Jul 18, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Sep 15, 2021; 12(9): 1550-1562
Published online Sep 15, 2021. doi: 10.4239/wjd.v12.i9.1550

Diabetes and COVID-19: Role of insulin resistance as a risk factor for COVID-19 severity

Charitha Gangadharan, Rupa Ahluwalia, Alben Sigamani

Charitha Gangadharan, Department of Clinical Research, Narayana Hrudayalaya Limited, Bangalore 560099, Karnataka, India

Rupa Ahluwalia, Consultant in Diabetes and Endocrinology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, United Kingdom

Alben Sigamani, Chief Scientific Officer, Numen Health, Bangalore 560095, Karnataka, India

Author contributions: Sigamani A conceived the idea; Gangadharan C wrote the first draft; Ahluwalia R contributed to the review, restructuring and modifications of the final draft; All the authors contributed for structuring and improvement of the final draft, and all approved the final draft.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Alben Sigamani, MBBS, MD, MSc, Professor, Chief Scientific Officer, Numen Health, No. 19, 4^th C Cross Koramangala Industrial, 5^th Block, Area, Bengaluru 560095, Karnataka, India. dralbens@numenhealth.com

Received: February 19, 2021
Peer-review started: February 19, 2021
First decision: May 12, 2021
Revised: June 11, 2021
Accepted: July 30, 2021
Article in press: July 30, 2021
Published online: September 15, 2021
Processing time: 199 Days and 21.1 Hours

Core Tip

Core Tip: Diabetes has been associated with an increased risk of developing coronavirus disease 2019 (COVID-19) as well as more severe outcomes as a consequence. The pathogenetic link between insulin resistance and COIVD-19 disease severity is not fully understood. Establishing an association between insulin resistance and COVID-19 severity can help to develop targeted therapeutic interventions and potentially improve outcomes amongst the at-risk group.